LDR brachytherapy offers superior tumor control to single‐fraction HDR prostate brachytherapy: A prospective study

LDR brachytherapy offers superior tumor control to single‐fraction HDR prostate brachytherapy: A prospective study

Purpose To compare the clinical outcomes of single‐fraction high‐dose‐rate (HDR) brachytherapy and single‐fraction low‐dose‐rate (LDR) brachytherapy as the sole treatment for primary prostate cancer. Material and Methods A quasi‐randomized study that allocated, from March 2008 to February 2012, 129...

Full description

Saved in:
Bibliographic Details
Published in:The Prostate Vol. 83; no. 11; pp. 1068 - 1075
Main Authors: Jimenez‐Garcia, Isabel E., Sabater, Sebastia, Martinez‐Gutierrez, Rocio, Sanchez‐Galiano, Pedro, Berenguer‐Serrano, Roberto, Castro‐Larefors, Susana, Rey‐Lopez, Irene, Ruiz‐Herrero, Beatriz, Sánchez‐Prieto, Ricardo, Rovirosa, Angeles, Arenas, Meritxell, Gonzalez‐Suarez, Herminio A.
Format: Journal Article
Language:English
Published: United States Wiley Subscription Services, Inc 01-08-2023
Subjects:
biochemical relapse‐free survival
Brachytherapy
Clinical outcomes
HDR
LDR
Patients
Prostate cancer
Radiation therapy
relapse
Survival
biochemical relapse-free survival
prostate cancer
LDR
brachytherapy
relapse
HDR
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Purpose To compare the clinical outcomes of single‐fraction high‐dose‐rate (HDR) brachytherapy and single‐fraction low‐dose‐rate (LDR) brachytherapy as the sole treatment for primary prostate cancer. Material and Methods A quasi‐randomized study that allocated, from March 2008 to February 2012, 129 low and intermediate risk prostate cancer patients to one single‐fraction HDR of 19 Gy (61 patients) or to a 145 Gy 125I LDR permanent implant (68 patients. Biochemical relapse‐free survival (bRFS) and overall survival (OS) were compared using the Kaplan–Meier method and Cox regression analysis. Results After a median follow‐up of 72 months in the HDR group, 26 patients relapsed, and after a median follow‐up of 84 months in the LDR group, 7 patients relapsed (p < 0.0001). The 5‐year bRFS was significantly better for the LDR group than for the HDR group (93.7% and 61.1%, respectively) (p < 0.0001). The 5‐year OS also was significantly better in the LDR group (95.5% vs. 89.9%) (p = 0.0436). Conclusions Permanent LDR prostate implant brachytherapy offers better clinical outcomes than single‐fraction HDR for prostate cancer.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:0270-4137
1097-0045
DOI:10.1002/pros.24548